Dr Lal PathLabs is focusing on innovation, including new wellness packages and high-end, super-speciality tests, with a focus on capturing prescription shares
Diagnostic chains are expanding laboratories, integrated centres and collection networks as demand grows for preventive, genomics-led and precision testing across India
Technical charts show Escorts, Hudco, Dr Lal PathLabs, Force Motors and Godrej Consumer were trading above the higher-end of the Bollinger Bands on the daily scale; and can potentially rally up to 23%
Domestic brokerage firm Nuvama analysts forecast a modest sequential slowdown but a healthy ~17 per cent year-on-year (Y-o-Y) Ebitda growth, led by hospitals and diagnostics.
Dr. Lal Path Labs shares rose 3.2 per cent on Wednesday, after it became the first laboratory in the country to adopt a deep learning-based AI module to detect lymph node metastas
Abbott India, Aurobindo Pharma, Cipla, Dr Lal PathLabs and Torrent Pharma flag caution signals on technical charts; here are the key levels to watch out for.
The company's consolidated net profit rose to Rs 96.7 crore ($11.2 million) in the three months to Dec. 31, from Rs 81.3 crore a year earlier, but fell short of analysts' estimate of Rs 97.69 crore
Apollo Hospitals, Vijaya Diagnostic and Narayana Hrudayalaya have given a fresh breakout on the daily scale. Charts show that these 5 healthcare related shares can rally up to 11 per cent.
Union Bank stock futures plunged nearly 8% on the back of 54% increase in OI. On the other hand, Dr. Lal Path Labs and Metropolis Health witnessed long build-up on Monday; shows derivatives data.
The Healthcare Federation of India reports that over 50 per cent of aspirational districts identified by NITI Aayog, which lack essential infrastructure, are served by diagnostic chains
